HEXADRONE
11.12.2023 08:31:35 CET | Business Wire | Press release
Hexadrone SAS, A French Modular UAV’s Manufacturer Created in 2014 has successfully completed GAP Analysis for The Tundra 2 in its Urban and Endurance versions versus DR EU 2019/945 with intension for Class Identification Label C5 and C6. With the achievement of this milestone, the certification process for both Urban and Endurance Version have been now formally triggered by Hexadrone to be performed by the notified body NavCert GmbH.
The Tundra 2 is bringing on the market a key differentiator by providing extreme modularity on UAVs, integrating unlimited type of payloads used in various sectors like, Surveillance, Geospatial, Agriculture, Oil and gas, Military, Homeland security, Rescue and much more.
“Through an in-depth analysis based on European Union (EU) Regulation 2019/945, we have ensured that the specifications of the Tundra 2 as well as our user manuals fully meet the current requirements. This compliance will ensure that the TUNDRA 2 users will be able to fly in European airspace legally, in accordance with categories C5 and C6, from 2024.
The exceptional modularity of the TUNDRA 2 offers reliable technical solutions for a variety of sectors. Due to its standardized interfaces, it can be easily extended using a multitude of addons while maintaining its compliance with current standards,”- says Alexandre Labesse, CEO of Hexadrone.
NavCert GmbH (NB 2603), currently chairs the coordination group of notified bodies for unmanned aircraft systems in accordance with the Delegated Regulation(EU) 2019/945. NavCert GmbH is one of the three entities in Europe which are appointed to perform C5/C6 class drone conformity tests, to be operated within the category specific, for performing operations Beyond Ground Observation (BGO) also known as Beyond Vision Line Of Sight (BVLOS).
Marcel Visser, CEO of NavCert GmbH, stated, “Congratulations to Hexadrone on being first confirming both multicopter C5 and C6 Drone specification compliancy to Delegated Regulation (EU) 2019/945. We are honored to be the Notified Body (NB 2603) selected by Hexadrone to perform Type Examinations for both version of the Tundra 2. Our extensive experience and our contribution to the development of the EN 4709 standard have been invaluable in conducting the technical assessments on unmanned aircraft systems for civil use. We remain dedicated to upholding the requisite standards of quality and safety for drone operations within the European Union."
*****
Starting 2024, Hexadrone is accelerating it’s worldwide expansion by selecting and recruiting Specialised resellers over the Globe.
About Hexadrone
Through its three Departments, Hexadrone is recognized as an expert in designing and manufacturing a modular UAV that gives customers a valuable investment for their activity. Founded in 2014, Hexadrone was initially providing a web platform to resel UAV components and quickly moved to the UAV custom assembling. Based on the user’s experiences feedback, Hexadrone has understood that a universal and modular platform was the answer to the market and after the first Version of the TUNDRA Hexadrone has built a factory to design and to manufacture a multi-purpose drone for professionals.
Today, the production capacity allowed to manufacture up to 1000 TUNDRA 2 units per year.
About NavCert GmbH
NavCert is the first laboratory ever accredited in Europe in the field of GNSS, nowadays with a flexible scope, a remarkable USP achievement. The firm provides worldwide technical services, like expert opinion, verification, validation, and voluntary certification services in the areas of precise positioning/localization, navigation, velocity and timing. Furthermore, NavCert is accredited as certification body for unmanned aircraft systems (UAS) by the Deutsche Akkreditierungsstelle (DAkkS) and is notified (NB 2603) by the German Federal Office of Civil Aeronautics for the EU Type Examination of fixed-wing, copter and multicopter UAS in classes C0 to C4 in the Open Category and C5 to C6 in the Specific Category according to the Delegated Regulation (EU) 2019/945 incl. referred standards. NavCert chairs the coordination group of notified bodies for UAS. These activities are complemented by GAP analysis of specification and documentation and pre-testing. For additional information, please visit NavCert website at www.navcert.de
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231210550915/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
GE HealthCare Announces First Patient Dosed in Phase 2/3 LUMINA Trial for Manganese-Based MRI Contrast Agent Under FDA Fast Track Designation, Further Advancing Its Innovation Pipeline of Novel Imaging Agents23.4.2026 13:29:00 CEST | Press release
Mangaciclanol, if approved, could transform contrast-enhanced MR imaging by offering an alternative to - or even replacing - gadolinium-based MRI agentsA manganese-based MRI contrast agent could address concerns with gadolinium-based contrast agents around retention in the body, security of supply, and the environment, with mangaciclanol’s clinical development under FDA Fast Track designationThe program demonstrates GE HealthCare’s commitment to advancing novel imaging agents to address unmet patient needs GE HealthCare (Nasdaq: GEHC) today announced the first patient has been dosed in the international, multi-center Phase 2/3 LUMINA clinical trial of its manganese-based magnetic resonance imaging (MRI) contrast agent, mangaciclanol, at Mayo Clinic in Rochester, Minnesota. Mangaciclanol, if approved, could offer an alternative to – or even replace – gadolinium-based MRI contrast agents, the current standard of care. The investigational agent has been granted Fast Track designation by t
Croma Pharma Launches AI-Driven Tech Venture to Revolutionize Aesthetic Medicine via Clinicore Platform23.4.2026 13:13:00 CEST | Press release
New structure to drive AI-powered innovation and international expansion Croma Pharma has launched a strategic joint venture to accelerate the development of Clinicore, its premium digital solution for aesthetic practices. This dedicated entity will focus on scaling the next generation of the platform while ensuring full continuity for existing users. Clinicore: Elevating Practice Excellence through AI Clinicore is a specialized SaaS (Software as a Service) solution designed to optimize the daily operations of aesthetic clinics. By automating patient management, scheduling, and administrative workflows, it enables healthcare professionals to focus entirely on patient care. A core element of the new strategy is a strong focus on Artificial Intelligence. Clinicore is evolving into a smart assistant, utilizing AI-driven features for automated treatment documentation, intelligent onboarding tools, and advanced process automation. This ensures that clinics can operate at maximum efficiency
NIQ Launches Commerce Lab to Build the Data and Measurement Layer for AI-Driven Commerce23.4.2026 13:00:00 CEST | Press release
NielsenIQ (NYSE: NIQ) today announced the launch of NIQ Commerce Lab, where the company is building the technology infrastructure for AI-driven commerce. The Lab will develop the data platforms, APIs, and measurement systems that power how products are discovered, evaluated, and purchased in AI-mediated environments. This includes what the industry often refers to as agentic commerce, but extends across quick commerce, social commerce, and other emerging channels—where AI is becoming the common layer shaping how consumers navigate choices and how decisions are made in real time. AI systems are rapidly moving from supporting decisions to making them—playing an increasingly central role in how commerce operates. Their effectiveness depends on the intelligence behind them. AI is Becoming the Operating Layer of Global Commerce NIQ ensures that the intelligence behind these systems is accurate, complete, and grounded in real-world behavior—reflecting how consumers actually buy, what product
Chiesi Reports Strong FY2025 Financial and Sustainability Results and Announces Leadership Transition Highlights23.4.2026 12:10:00 CEST | Press release
Strong FY2025 financial and sustainability results; leadership transition will support continuity and long-term growth Revenue up 8.2% to €3.6bn with double-digit growth in Rare Diseases and U.S. market Air sales at €1.886bn, growing 3.9% vs. 2024 - Care sales at €904m growing 13.3% vs. 2024 - Rare sales at €906m, growing 22.3% vs. 2024 Giuseppe Accogli leaving to pursue another opportunity, Group CFO Jean-Marc Bellemin named Interim CEO while new CEO search is underway Record €885m Research & Development (R&D) investment underscores continued commitment to innovation across respiratory, rare disease and specialty care Sustainability leadership further strengthened through B Corp recertification and progress on Carbon Minimal Inhaler (CMI) innovation Chiesi Group (“Chiesi”), an international research‑focused biopharmaceutical company and certified B Corp, today announced its financial results for the year ended 31 December 2025. Chiesi reported €3.625 billion in consolidated revenues,
REPLY S.p.A.: Shareholders’ Meeting Approves the 2025 Financial Statements23.4.2026 12:05:00 CEST | Press release
Consolidated turnover of €2,483.6 million (€2,300.5 million in 2024);Group net profits of €250.9 million (€211.1 million in 2024).Approval of the proposal to distribute a dividend of €1.35 per share.Approval of the plan for the purchase and/or disposal of treasury shares. The General Shareholders’ meeting of Reply S.p.A. [EXM, STAR: REY] held today approved the Financial Statements for the financial year 2025, confirming the distribution of a gross dividend of €1.35 per share. The dividend will be paid on 20 May 2026, with dividend date set on 18 May 2026 (record date on 19 May 2026). Approval of the 2025 financial statements The Reply Group closed the 2025 financial year with a consolidated turnover of €2,483.6 million, recording a 8.0% increase compared to €2,300.5 million in 2024. Consolidated EBITDA was €467.6 million, up 13.9% compared to €410.6 million recorded for the year 2024. EBIT, from January to December, was €397.1 million, up 18.5% compared to €330.4 million recorded for
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom